2025-07-28 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the provided data. The report will be in English, with key numbers highlighted, followed by a summary of the analysis.

**Recursion Pharmaceuticals Inc (RXRX) Stock Analysis**

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -39.95%
*   **VOO Cumulative Return:** 38.76%
*   **Absolute Divergence:** -80.1 (RXRX is lagging S&P 500 significantly)
*   **Relative Divergence:** 6.5 (RXRX is near its historical low relative to the S&P 500)

**Alpha/Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2021-2023  | 5.0%  | 73.6% | -1.0%  | -0.1 | 4.3   |
| 2022-2024  | 0.0%  | 73.6% | -25.0% | 0.1  | 2.9   |
| 2023-2025  | 12.0% | 73.6% | -40.0% | 0.1  | 2.8   |

**Analysis:**

*   **Significant Underperformance:** RXRX has significantly underperformed the S&P 500 over the period. The cumulative return difference is substantial.
*   **Relative Divergence Interpretation:** A relative divergence of 6.5 indicates that RXRX's performance relative to the S&P 500 is near the lower end of its historical range. It is very low relative to its history, suggesting significant underperformance compared to the benchmark.
*   **Alpha/Beta:** The negative Alpha values indicate that RXRX has consistently underperformed relative to what its Beta would suggest. Beta is relatively low and close to zero. RXRX's market cap has decreased from 4.3B to 2.8B.
*   **CAGR:** 2023-2025 is higher CAGR than other period.

**2. Recent Stock Price Movement**

*   **Current Price:** 6.49
*   **Previous Close:** 6.26
*   **Change:** 3.67%
*   **5-Day Moving Average:** 6.424
*   **20-Day Moving Average:** 5.598
*   **60-Day Moving Average:** 5.0377

**Analysis:**

*   **Recent Uptick:** The stock shows a positive change of 3.67%. The current price is above all moving averages, suggesting a recent upward trend.
*   **Moving Average Confirmation:** The 5-day moving average is above the 20-day and 60-day moving averages, further confirming the short-term upward momentum.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 75.08 (Overbought)
*   **PPO:** 1.6856
*   **Hybrid Signal:** cash_0%_Buy 80% of cash
*   **Recent (20-day) Relative Divergence Change:** +3.8 (Short-term increase)
*   **Expected Return (%):** -370.1%

**Analysis:**

*   **Market Risk:** The MRI indicates a low-risk environment, which may be misleading given the stock's high volatility.
*   **RSI:** The high RSI value (75.08) suggests the stock is overbought and might be due for a correction.
*   **PPO:** The positive PPO indicates that the short-term moving average is above the long-term moving average.
*   **Hybrid Signal:** The signal "cash_0%_Buy 80% of cash" indicates a buy signal, but with caution due to the MRI value.
*   **Recent Divergence Change:** The positive change in relative divergence suggests short-term bullish momentum.
*   **Expected Return:** The very negative expected return (-370.1%) is concerning. This suggests that, based on current data and models, the stock is expected to significantly underperform the S&P 500 over the long term. The jump in price might be unsustainable given the low expected return.

**4. Recent News & Significant Events**

*   **July 26, 2025:** Major business developments, regulatory changes, or market events.
*   **July 28, 2025:** Analyst discussions on recent performance and outlook.
*   **July 24, 2025:** Notable stock volatility.
*   **July 25, 2025:** Market experts highlighting both risks and opportunities.

**Analysis:**

*   **Recent News Impact:** The recent news suggests that the company is experiencing significant events that are affecting its stock price. The volatility and analyst discussions indicate that the market is actively evaluating the company's prospects. Investors should monitor company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-05 | -0.5  | 0.01 B$     |
| 2024-11-06 | -0.34 | 0.03 B$     |
| 2024-08-08 | -0.4  | 0.01 B$     |
| 2024-05-09 | -0.39 | 0.01 B$     |
| 2025-05-05 | -0.39 | 0.01 B$     |

**Analysis:**

*   **Consistent Losses:** The company has consistently reported negative EPS, indicating ongoing losses.
*   **Low Revenue:** Revenue remains relatively low. The fact that the EPS remains negative, even with revenues in the millions, suggests high operating costs.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B | -47.31%      |
| 2024-12-31 | $0.00B | -183.62%     |
| 2024-09-30 | $0.03B | 53.69%       |
| 2024-06-30 | $0.01B | 36.14%       |
| 2024-03-31 | $0.01B | 17.23%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-03-31 | $0.93B    | -21.68%  |
| 2024-12-31 | $1.03B    | -17.29%  |
| 2024-09-30 | $0.52B    | -18.27%  |
| 2024-06-30 | $0.58B    | -16.69%  |
| 2024-03-31 | $0.40B    | -22.78%  |

**Analysis:**

*   **Inconsistent Profitability:** Profit margins are highly volatile, with some quarters showing positive margins but others showing significant losses.
*   **Declining Equity:** Equity has fluctuated but shows a general decline.
*   **Negative ROE:** The negative ROE indicates that the company is not generating profits from its equity.

**7. 종합 Analysis**

**Summary:**

RXRX has significantly underperformed the S&P 500, with a negative expected return and an overbought RSI suggesting a potential pullback. Despite recent positive price movement, the company's financial performance shows consistent losses, volatile profit margins, and declining equity.

**Recommendation:**

Given the significant underperformance, negative expected return, high RSI, and concerning financial data, a cautious approach is advised. The recent price surge should be viewed with skepticism, and further research into the "major business developments" mentioned in the news is warranted. While the hybrid signal suggests a buy, the overall risk profile appears high. Invest with extreme caution and closely monitor the company's financial results and announcements.
